Jul 2, 2025 7:00am EDT Tonix Pharmaceuticals Announces Peer-Reviewed Publication in Cancer Cell Journal Highlighting Positive Preclinical Data of mTNX-1700 in Gastric Cancer Animal Models
Jun 30, 2025 7:00am EDT Tonix Pharmaceuticals Announces Inclusion in the Russell 3000® and Russell 2000® Indexes
Jun 16, 2025 7:00am EDT Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the Annual European Congress of Rheumatology (EULAR) 2025
Jun 13, 2025 7:00am EDT Tonix Pharmaceuticals Announces Appointment of Commercial Industry Veteran, James “Jim” Hunter, to Board of Directors
Jun 10, 2025 7:00am EDT Tonix Pharmaceuticals Announces Presentation at the 2025 BIO International Convention
Jun 5, 2025 7:00am EDT Tonix Pharmaceuticals Announces Poster Presentation at the Annual European Congress of Rheumatology (EULAR) 2025
May 22, 2025 7:00am EDT Tonix Pharmaceuticals Announces Presentation at the A.G.P. Annual Healthcare Company Showcase
May 21, 2025 7:00am EDT Tonix Pharmaceuticals Announces First Patient Dosed in Phase 2 OASIS Study of TNX-102 SL for Reduction of Acute Stress Reaction
May 14, 2025 7:00am EDT Tonix Pharmaceuticals Announces Appointment of Joseph Hand, Esq., as General Counsel and Executive Vice President of Operations
May 12, 2025 4:30pm EDT Tonix Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Highlights
